Parallel Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $856K | Buy |
1,107
+112
| +11% | +$85.7K | 0.02% | 529 |
|
|
2025
Q4 | $769K | Buy |
995
+94
| +10% | +$63.8K | 0.01% | 532 |
|
|
2025
Q3 | $507K | Buy |
901
+159
| +21% | +$89.9K | 0.01% | 657 |
|
|
2025
Q2 | $389K | Sell |
742
-233
| -24% | -$130K | 0.01% | 729 |
|
|
2025
Q1 | $618K | Sell |
975
-129
| -12% | -$88.7K | 0.01% | 513 |
|
|
2024
Q4 | $786K | Sell |
1,104
-220
| -17% | -$185K | 0.02% | 459 |
|
|
2024
Q3 | $1.39M | Buy |
1,324
+73
| +6% | +$81.2K | 0.03% | 307 |
|
|
2024
Q2 | $1.32M | Buy |
1,251
+100
| +9% | +$96.9K | 0.03% | 300 |
|
|
2024
Q1 | $1.11M | Buy |
1,151
+166
| +17% | +$158K | 0.03% | 338 |
|
|
2023
Q4 | $865K | Sell |
985
-628
| -39% | -$517K | 0.03% | 366 |
|
|
2023
Q3 | $1.33M | Buy |
1,613
+72
| +5% | +$56.6K | 0.04% | 259 |
|
|
2023
Q2 | $1.11M | Sell |
1,541
-9
| -0.6% | -$6.94K | 0.04% | 302 |
|
|
2023
Q1 | $1.27M | Sell |
1,550
-60
| -4% | -$45.3K | 0.04% | 272 |
|
|
2022
Q4 | $1.16M | Sell |
1,610
-103
| -6% | -$76K | 0.05% | 233 |
|
|
2022
Q3 | $1.18M | Sell |
1,713
-132
| -7% | -$83.1K | 0.05% | 213 |
|
|
2022
Q2 | $1.09M | Buy |
1,845
+790
| +75% | +$514K | 0.05% | 226 |
|
|
2022
Q1 | $730K | Sell |
1,055
-50
| -5% | -$31.6K | 0.03% | 331 |
|
|
2021
Q4 | $698K | Buy |
1,105
+63
| +6% | +$38.7K | 0.03% | 346 |
|
|
2021
Q3 | $631K | Buy |
1,042
+441
| +73% | +$274K | 0.03% | 347 |
|
|
2021
Q2 | $336K | Buy |
601
+97
| +19% | +$49.1K | 0.01% | 500 |
|
|
2021
Q1 | $238K | Sell |
504
-193
| -28% | -$94K | 0.01% | 579 |
|
|
2020
Q4 | $337K | Sell |
697
-194
| -22% | -$105K | 0.02% | 420 |
|
|
2020
Q3 | $499K | Buy |
891
+236
| +36% | +$143K | 0.03% | 307 |
|
|
2020
Q2 | $408K | Buy |
655
+101
| +18% | +$57.3K | 0.03% | 345 |
|
|
2020
Q1 | $270K | Buy |
554
+203
| +58% | +$83.7K | 0.02% | 372 |
|
|
2019
Q4 | $132K | Buy |
351
+73
| +26% | +$24.6K | 0.01% | 664 |
|
|
2019
Q3 | $77K | Sell |
278
-52
| -16% | -$15.4K | 0.01% | 814 |
|
|
2019
Q2 | $103K | Sell |
330
-65
| -16% | -$21.6K | 0.01% | 658 |
|
|
2019
Q1 | $162K | Buy |
395
+25
| +7% | +$10.3K | 0.02% | 473 |
|
|
2018
Q4 | $138K | Sell |
370
-99
| -21% | -$36.2K | 0.02% | 454 |
|
|
2018
Q3 | $189K | Buy |
469
+63
| +16% | +$24K | 0.02% | 402 |
|
|
2018
Q2 | $140K | Sell |
406
-57
| -12% | -$17.8K | 0.02% | 452 |
|
|
2018
Q1 | $159K | Sell |
463
-38
| -8% | -$13.2K | 0.02% | 387 |
|
|
2017
Q4 | $188K | Sell |
501
-125
| -20% | -$50.6K | 0.03% | 330 |
|
|
2017
Q3 | $246K | Sell |
626
-25
| -4% | -$11.9K | 0.04% | 281 |
|
|
2017
Q2 | $320K | Sell |
651
-435
| -40% | -$190K | 0.06% | 236 |
|
|
2017
Q1 | $442K | Buy |
1,086
+59
| +6% | +$21.9K | 0.09% | 166 |
|
|
2016
Q4 | $377K | Buy |
+1,027
| New | +$391K | 0.09% | 164 |
|
Other funds holding REGN
VCM
N
Parallel Advisors's REGN Position: Q1 2026 in Review
Parallel Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $85.7K and bringing the position to 1,107 shares worth $856K. The position accounts for 0.02% of the portfolio, ranked #529.
Parallel Advisors first reported a position in REGN in Q4 2016 and has held it in 38 quarters since. The position peaked at $1.39M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Parallel Advisors held 1,107 shares of Regeneron Pharmaceuticals worth $856K as of Q1 2026.
- Parallel Advisors bought 112 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $85.7K.
- Regeneron Pharmaceuticals made up 0.02% of Parallel Advisors's portfolio in Q1 2026, its #529 holding.
- Parallel Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Regeneron Pharmaceuticals position peaked at $1.39M in Q3 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.